| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +27,532 | 2.3% | $43.12 | +$1,187,235 |
| Sells | 14 | -1,172,736 | 98% | $44.44 | -$52,120,387 |
| Net | -13 | -1,145,204 | -95% | -$50,933,152 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Michael Morrissey | President and CEO, Director | $155,683,701 | 24 Feb 2026 | ||
| David Edward Johnson | Director | $67,687,536 | +$1,187,235 | +1.8% | 25 Nov 2025 |
| Stelios Papadopoulos | Director | $51,790,879 | -$5,974,130 | -10% | 12 Nov 2025 |
| Christopher J. Senner | EVP and CFO | $44,305,201 | -$7,410,998 | -14% | 26 Feb 2026 |
| Jeffrey Hessekiel | EVP & General Counsel | $32,059,538 | -$1,154,500 | -3.5% | 15 May 2025 |
| Dana Aftab | EVP, Research and Development | $28,966,757 | -$5,572,308 | -16% | 26 Feb 2026 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | $21,161,419 | -$3,309,125 | -14% | 15 May 2025 |
| Patrick J. Haley | EVP, Commercial | $18,153,333 | -$14,001,464 | -44% | 26 Feb 2026 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | $16,092,480 | 26 Jul 2021 | ||
| Jack L. Wyszomierski | Director | $12,320,247 | -$4,706,935 | -28% | 18 Feb 2026 |
| Peter Lamb | EVP, Scientific Strategy & CSO | $9,785,520 | 15 Dec 2022 | ||
| Lance Willsey | Director | $9,702,127 | 26 May 2022 | ||
| Vicki L. Goodman | EVP, Prod Dev & Med Aff &CMO | $7,032,970 | 03 Apr 2023 | ||
| George Poste | Director | $6,468,353 | -$948,958 | -13% | 29 May 2025 |
| Charles Cohen | Director | $5,975,033 | 31 Dec 2021 | ||
| Brenda Hefti | SVP and General Counsel | $5,379,290 | -$821,623 | -13% | 26 Feb 2026 |
| Maria C. Freire | Director | $3,646,623 | 29 May 2025 | ||
| Marchesi Vincent T. | Director | $2,148,589 | 26 May 2022 | ||
| Tomas J. Heyman | Director | $1,529,339 | -$201,254 | -12% | 29 May 2025 |
| Jacqueline Wright | Director | $1,183,142 | 01 Jun 2023 | ||
| Bob Oliver | Director | $927,168 | -$1,325,339 | -59% | 13 Feb 2026 |
| Julie Smith | Director | $912,136 | -$4,687,346 | -84% | 17 Feb 2026 |
| Mary C. Beckerle | Director | $895,822 | -$1,032,414 | -54% | 11 Nov 2025 |
| Alan M. Garber | Director | $857,229 | 21 Mar 2024 | ||
| Sue Gail Eckhardt | Director | $767,375 | -$973,994 | -56% | 13 Feb 2026 |
| Carl B. Feldbaum | Director | $427,505 | 09 Feb 2023 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dana Aftab | EXEL | Common Stock | Award | 8.44% | 52,018 | 668,124 | 26 Feb 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Award | 5.33% | 52,018 | 1,028,110 | 26 Feb 2026 | Direct | ||
| Brenda Hefti | EXEL | Common Stock | Award | 24% | 23,119 | 119,631 | 26 Feb 2026 | Direct | ||
| Patrick J. Haley | EXEL | Common Stock | Award | 10.6% | 40,459 | 422,367 | 26 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Award | 11% | 160,437 | 1,614,552 | 26 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Gift | -4.8% | -100,278 | 1,989,956 | 24 Feb 2026 | By Trust | ||
| Dana Aftab | EXEL | Common Stock | Sale | -7.22% | $2,132,351 | $44.50 | -47,918 | 616,106 | 24 Feb 2026 | Direct |
| Dana Aftab | EXEL | Common Stock | Sale | -4.31% | $1,324,868 | $44.35 | -29,873 | 664,024 | 19 Feb 2026 | Direct |
| Jack L. Wyszomierski | EXEL | Common Stock | Sale | -26.2% | $4,382,252 | $44.01 | -99,574 | 279,942 | 18 Feb 2026 | Direct |
| Jack L. Wyszomierski | EXEL | Common Stock | Options Exercise | 5.75% | 20,634 | 379,516 | 18 Feb 2026 | Direct | ||
| Jack L. Wyszomierski | EXEL | Option (right to buy) | Options Exercise | -100% | -20,634 | 0 | 18 Feb 2026 | Direct | ||
| Julie Smith | EXEL | Common Stock | Sale | -75.7% | $2,849,200 | $44.44 | -64,117 | 20,590 | 18 Feb 2026 | Direct |
| Julie Smith | EXEL | Common Stock | Options Exercise | 11449.5% | 64,117 | 64,677 | 18 Feb 2026 | Direct | ||
| Julie Smith | EXEL | Option (right to buy) | Options Exercise | -100% | -64,117 | 0 | 18 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Gift | 6.37% | 125,094 | 2,090,234 | 18 Feb 2026 | By Trust | ||
| Michael Morrissey | EXEL | Common Stock | Gift | -7.92% | -125,094 | 1,454,115 | 18 Feb 2026 | Direct | ||
| Brenda Hefti | EXEL | Common Stock | Sale | -16.2% | $821,623 | $44.01 | -18,669 | 96,512 | 18 Feb 2026 | Direct |
| Julie Smith | EXEL | Common Stock | Sale | -67.3% | $1,838,145 | $43.33 | -42,422 | 20,590 | 17 Feb 2026 | Direct |
| Julie Smith | EXEL | Common Stock | Options Exercise | 206% | 42,422 | 63,012 | 17 Feb 2026 | Direct | ||
| Julie Smith | EXEL | Option (right to buy) | Options Exercise | -100% | -42,422 | 0 | 17 Feb 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Sale | -3.04% | $1,337,044 | $43.67 | -30,617 | 976,092 | 17 Feb 2026 | Direct |
| Patrick J. Haley | EXEL | Common Stock | Sale | -15.1% | $2,950,941 | $43.52 | -67,814 | 381,908 | 17 Feb 2026 | Direct |
| Michael Morrissey | EXEL | Common Stock | Gift | 14.6% | 250,736 | 1,965,140 | 17 Feb 2026 | By Trust | ||
| Michael Morrissey | EXEL | Common Stock | Gift | -13.7% | -250,736 | 1,579,209 | 17 Feb 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Tax liability | -3.44% | -35,870 | 1,006,709 | 15 Feb 2026 | Direct | ||
| Patrick J. Haley | EXEL | Common Stock | Tax liability | -6.54% | -31,483 | 449,722 | 15 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Tax liability | -6.17% | -120,390 | 1,829,945 | 15 Feb 2026 | Direct | ||
| Dana Aftab | EXEL | Common Stock | Tax liability | -5.35% | -39,205 | 693,897 | 15 Feb 2026 | Direct | ||
| Brenda Hefti | EXEL | Common Stock | Tax liability | -4.5% | -5,430 | 115,181 | 15 Feb 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Sale | -3.18% | $1,473,954 | $43.00 | -34,278 | 1,042,579 | 13 Feb 2026 | Direct |
| Michael Morrissey | EXEL | Common Stock | Tax liability | -15.9% | -369,606 | 1,950,335 | 13 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Options Exercise | 27.1% | 494,700 | 2,319,941 | 13 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Option (right to buy) | Options Exercise | -100% | -494,700 | 0 | 13 Feb 2026 | Direct | ||
| Sue Gail Eckhardt | EXEL | Common Stock | Sale | -18% | $168,854 | $43.79 | -3,856 | 17,524 | 13 Feb 2026 | Direct |
| Bob Oliver | EXEL | Common Stock | Sale | -58.9% | $1,325,339 | $43.81 | -30,250 | 21,120 | 13 Feb 2026 | Direct |
| Bob Oliver | EXEL | Common Stock | Options Exercise | 21.5% | 9,088 | 51,370 | 13 Feb 2026 | Direct | ||
| Bob Oliver | EXEL | Option (right to buy) | Options Exercise | -42.9% | -9,088 | 12,118 | 13 Feb 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Tax liability | -7.1% | -139,524 | 1,825,241 | 15 Jan 2026 | Direct | ||
| Michael Morrissey | EXEL | Common Stock | Award | 38.7% | 548,073 | 1,964,765 | 15 Jan 2026 | Direct | ||
| Dana Aftab | EXEL | Common Stock | Tax liability | -3.58% | -27,254 | 733,102 | 15 Jan 2026 | Direct | ||
| Dana Aftab | EXEL | Common Stock | Award | 18.7% | 119,578 | 760,356 | 15 Jan 2026 | Direct | ||
| Patrick J. Haley | EXEL | Common Stock | Tax liability | -6.3% | -32,332 | 481,205 | 15 Jan 2026 | Direct | ||
| Patrick J. Haley | EXEL | Common Stock | Award | 37.3% | 139,508 | 513,537 | 15 Jan 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Tax liability | -3.62% | -40,459 | 1,076,857 | 15 Jan 2026 | Direct | ||
| Christopher J. Senner | EXEL | Common Stock | Award | 15.4% | 149,474 | 1,117,316 | 15 Jan 2026 | Direct | ||
| Brenda Hefti | EXEL | Common Stock | Award | 33.4% | 30,170 | 120,611 | 03 Dec 2025 | Direct | ||
| David Edward Johnson | EXEL | Common Stock | Purchase | 1.8% | $1,187,235 | $43.12 | 27,532 | 1,553,262 | 25 Nov 2025 | See footnote |
| Patrick J. Haley | EXEL | Common Stock | Sale | -6.97% | $1,194,071 | $42.58 | -28,043 | 374,029 | 21 Nov 2025 | Direct |
| Dana Aftab | EXEL | Common Stock | Gift | -3.61% | -24,000 | 640,778 | 21 Nov 2025 | Direct | ||
| Patrick J. Haley | EXEL | Common Stock | Sale | -100% | $444,767 | $41.77 | -10,648 | 0 | 20 Nov 2025 | By 401(k) |